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Introduction
 Well differentiated thyroid cancer (WDTC) which 
includes papillary (PTC) and follicular thyroid cancers 
(FTC) is an uncommon malignancy with a reported 
worldwide incidence of 0.5-10/100,000 population 
(Franceschi and Vecchia, 1994).  These tumors have an 
indolent clinical course with late relapse. The outcome 
of patients with WDTC has been determined by multiple 
factors. It has been reported that higher recurrence is 
closely linked to lymph node metastasis (Coburn and 
Wanebo, 1992). Increasing primary tumor size (PTS) has 
been found to have correlation with an increased risk of 
extrathyroidal growth and distant metastasis (Machens et 
al., 2005). However, the single most important determinant 
of survival in this condition is distant metastasis [worse 
with bone metastasis] (DeGroot et al., 1990) with the 
median survival of 4.1 years (Shoup et al., 2003). A PTS 
of > 2 cm has been considered as a threshold for distant 
metastasis and as a demarcation between T1 and T2 lesions 
by American Thyroid Association (ATA) in its recent 
guidelines (Cooper et al., 2009). 
	 The	aim	of	this	study	was	to	find	out	threshold	primary	
tumour sizes for developing nodal, pulmonary, bone and 
over all distant metastasis.
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Abstract
 Background: In papillary and follicular thyroid cancers (PTC, FTC), nodal and distant metastasis are 
generally considered important determinants of recurrence and survival, respectively. However, there is no 
consensus about the threshold primary tumour size (PTS) for these determinants. The aim of this study was to 
assess size relationships for developing nodal, pulmonary, bone and overall distant metastases. Methods:  This 
prospective study covered 139 (93 females and 46 males) consecutive biopsy proven patients with PTC (114/139, 
mean age 41.0 ±15.7 years, M: F, 35%:65%) and FTC (25/139, mean age 39.2 ± 14.3 years, M: F: 24%:76%). 
Results: Average primary tumor size was 23.4 ± 11.1 mm and 26.5 ± 13.1 mm for PTC and FTC respectively 
(p value=0.223). Nodal metastasis was found more common in PTC than FTC (49% vs 28%, p value <0.05), 
whereas overall distant metastasis was approximately the same (13% and 24%, p value =0.277); however, bone 
metastasis was significantly higher in FTC than PTC (24% vs 5%, p value <0.05). Cumulative risk for nodal 
and distant metastases for FTC and PTC starts at PTS <20 mm and may indicate an unusual aggressive tumor 
behavior in the studied population. Highest cumulative risk for nodal and pulmonary metastases in PTC and 
for bone metastasis in FTC was found to be ≥50 mm PTS. Conclusion: We conclude that a PTS of <20 mm may 
indicate an unusual aggressive tumor behavior with highest cumulative risk for nodal and pulmonary metastases 
in PTC and for bone metastasis in FTC with a cutoff of ≥50 mm. 
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Materials and Methods
 This is a prospective study which included 139 (93 
females and 46 males) consecutive biopsy proven patients 
with WDTC who attended nuclear medicine section of 
Karachi Institute of Radiotherapy and Nuclear Medicine 
(KIRAN), Karachi, Pakistan for radioiodine-131 (131I) 
treatment from January 2005 till July 2011. These patients 
were referred from The Aga Khan University Hospital 
(AKUH), Karachi, Pakistan. The study was duly approved 
by the ethical committee of the Institute. We included 
only those patients who had complete information of PTS 
as mentioned in their histopathology reports, ultrasound 
neck,  serum TSH >30 IU/ml, stimulated thyroglobulin 
level with antibodies, 131I ablation and a post therapy 
whole body iodine scan (WBIS). Patients with no 
information about tumor size in histopathology reports 
and histopathology other than PTC, follicular variant of 
PTC and FTC (like Hurtle cell, tall, columnar, sclerosing 
or insular type or well differentiated tumor of unknown 
malignant	potential	)	were	excluded.		For	confirmation	of	
nodal metastasis histopathology was used as gold standard 
while 131I avid distant metastases (lung, bone or soft tissue) 
seen	on	WBIS	were	confirmed	by	imaging	modalities	like	
ultrasound, CT and MRI. 
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Statistical Analysis 
 Categorical and continuous data were tested on 
univariate analysis using the two-tailed Chi Square test. 
For comparative analysis of cumulative risks between both 
tumor entities, the Kaplan–Meier method (log-rank test) 
was	used.	The	level	of	significance	was	set	at	P<	0.05.	
Commercial statistical software packages (SPSS version 
12 and MedCalc®) were used.
Results 
 We included biopsy proven 114/139 (82%) patients 
(mean age 40.96 ±15.7 years, M: F, 35%:65%) of PTC and 
25/139 (18%) cases (mean age 39.16 ± 14.29 years, M: F: 
24%:76%) of FTC. Out of these 139 patients, 103 had total 
thyroidectomy, 36 had completion thyroidectomy and in 
63 patients nodal dissection was also performed (Table 1). 
Average primary tumor size was 23.4 ± 11.1 mm and 26.5 
± 13.1 mm for PTC and FTC respectively (p value=0.223). 
Nodal metastasis was found more common in PTC than 
FTC	(49%	Vs	28%,	p	value	<0.05).	Cumulative	frequency	
risk for nodal metastasis in PTC rises linearly with PTS 
(starting at a PTS of 8-10 mm) (Figure 1). For FTC, 
cumulative frequency risk for nodal metastasis increases 
with a PTS  between 12-25 mm followed by a plateau up 
to 50 mm and then an exponential rise is seen after > 50 
mm	PTS	(p	value	<0.05;	Log	rank).		Incidence	of	overall	
distant metastasis was same for PTC and FTC (13% and 
24%, p value=0.277, Table 1) with a congruent cumulative 




bony metastasis was started at PTS of 12 mm or more in 
a linear trend up to 25 mm followed by constant response 
between 25-50 mm when an exponential rise was  noted 
at	50mm	(p	value	<0.05;	Log	rank,	Figure	3).	For	PTC,	
the cumulative risk for bone metastasis shows progressive 
rise for a PTS of 15-25 mm then followed by plateau in 
rest of its course. Similarly, the incidence of pulmonary 
metastasis was same (p value=0.818, Table 1). In PTC 
the cumulative frequency risk for pulmonary metastasis 
showed an initial linear relation at PTS 20-25 mm then 
a constant response between 25-38 mm followed by an 
exponential ascend. In FTC the cumulative frequency 
risk for pulmonary metastasis was observed at PTS of 12 
mm with a slight rise till 25 mm and then it followed a 
constant	response	(p	value	=	0.59;	Log	rank,	Figure	4).
Figure 1. Cumulative Frequency Risk for Nodal 
Metastasis with Relation to Primary Tumor Size of 
Papillary and Follicular Thyroid Cancers
Figure 2. Cumulative Frequency Risk for Overall 
Distant Metastases with Relation to Primary Tumor 
Dize of Papillary and Follicular Thyroid Cancers
Figure 3. Cumulative Frequency Risk for Bone 
Metastasis with Relation to Primary Tumor Size of 
Papillary and Follicular Thyroid Cancers
Figure 4. Cumulative Frequency Risk for Pulmonary 
Metastasis with Relation to Primary Tumor Size of 
Papillary and Follicular Thyroid Cancers
Table 1. Patients’ Demographics
                   Papillary Thyroid  Follicular Thyroid  p value
                                             Carcinoma (PTC)  Carcinoma (FTC)
                                                       (114)        (25)  
Age (mean± SD) years  40.96 ± 15.7 39.16 ±14.29 0.588
Male  40 (35%) 06 (24%) 0.409
Female 74 (65%) 19 (76%) 
Primary Tumor Size   
Mean ± SD in mm 23.4 ± 11.1 26.5 ± 13.1 0.223
Post-op Thyroglobulin   
Median (range) ng/dl 14 (0.15-12000) 77 (3.5-6900) 0.194
Pot-op TSH   
Median	(range)	IU/L	 60	(2.25-100)	 50	(5-100)	 0.138
Nodal Metastases 56 (49%) 7 (28%) 0.046*
Distant Metastases   
  Overall 15 (13%) 6 (24%) 0.277
  Bone 06 (5%) 6 (24%) 0.006*
  Pulmonary 10 (9%) 2 (8%) 0.818
SD,	 Standard	 Deviation;	 TSH,	 Thyroid	 Stimulating	 Hormones;	
*p<0.05	(statistically	significant)
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Discussion
According to various reports patients with FTC are 
on average 3-6 years older and have larger PTS than PTC 
(Mazaferri	and	Jhiang	1994;	Hölzer	et	al.,	1996;	Hundahl	
et	al.,	1996).	A	delay	in	diagnosis	due	to	inability	of	fine	
needle aspiration (FNA) to delineate between adenoma 
and carcinoma (Cerutti et al., 2004) is supposed to be 
one of the major factors. However, in this study PTS and 
mean age of patients with FTC and PTC were marginally 
different	(non-significant	p	values).	The	most	plausible	
explanation for this fact might be an early referral and 
proactive approach employed in patients with thyroid 
nodule resulted in early diagnosis of follicular neoplasm.
Cumulative risk for nodal metastasis for PTC was 
higher than FTC due to early and predominant nodal 
spread of PTC as indicated by steeper curve for PTC. 
However, position of anchoring points on the ordinate (x 
intercept) of the curves showed a threshold PTS of 8-10 
mm for PTC and 12-14 mm for FTC. This is an important 
finding	in	this	study	as	thyroid	nodules	<20mm	size	are	
considered	low	risk	and	TNM	classification	has	used	20	
mm demarcation between T1 and T2 lesions (Sobin and 
Wittekind, 2002). Exponential rise in nodal metastasis in 
FTC after 50mm PTS may be explained by higher degree 
of invasion associated with larger tumor size (Asari et 
al., 2009). Incidence of nodal metastasis in PTC in this 
study is 56% which coincides with reported incidence 
of	 23-56%	 (Grebe	 and	Hay,	 1996;	 Shaha,	 1998)	 but	
incidence of nodal metastasis in FTC in our study (28%) 
is higher than the reported incidence of 5-13% (Soh and 
Clark, 1996). Higher incidence of nodal metastasis in 
FTC	and	at	a	PTS	<20	mm	(both	FTC	and	PTC)	in	this	
study indicate a possible aggressive behavior of disease 
in studied population which needs further studies for 
precise evaluation.  
In our study the incidence of distant metastasis overall 
was	statistically	not	 significant	between	PTC	and	FTC	
and this is in contrary to most of the published studies 
which show higher incidence in FTC (Shaha et al., 1997).
This fact may be explained by small sample size of FTC 
cohort. Another possible explanation might be an unusual 
aggressive nature thyroid cancer in our region as depicted 
by an appreciable number of nodal metastasis with small 
PTS and congruent cumulative risk for distant metastasis 
overall with respect to PTS. Higher incidence of bone 
metastasis in FTC with a linear cumulative frequency risk 
with respect to PTS is explained by hematogenous spread 
of tumor (Schlumberger, 1998) and this correlates well with 
the reported incidence (Durante et al., 2006). However, 
there are reports which found no difference between PTC 
and FTC for cumulative risks of distant metastasis to 
the bone (Machens and Wanebo, 2005). The cumulative 
frequency risk of PTC shows a relatively persistent and 
low risk for bony metastasis for increasing PTS and this 
could be explained by well known predominant nodal 
route of dissemination of PTC. However, FTCs show an 
exponential rise in risk of bone metastasis for PTS >50 
mm (approaching almost 100%) which denotes threshold 
PTS > 50 mm as an important predictor of bone metastasis 
in FTC. The incidence of pulmonary metastasis in FTC 
and	PTC	are	statistically	similar	(non	significant	p	value)	
and this is concurred with published data (Machens and 
Wanebo, 2005). The cumulative frequency risk of FTC 
for pulmonary metastasis shows a low but appreciable 
risk even for tumor size between 10-20 mm which draws 
attention towards a possible aggressive tumor nature in 
studied population. The cumulative risk of pulmonary 
metastasis for PTC shows a progressive increase and an 
exponential rise (>60%) for a PTS >50 mm (threshold 
size to predict pulmonary metastasis for PTC). We don’t 
have any plausible explanation for predilection of PTC 
for pulmonary metastasis and FTC for bone metastasis 
for a threshold PTS of 50 mm and needs more studies to 
probe this aspect of pathogenesis.
We conclude that (1) Cumulative risk for nodal and 
extra-nodal metastases for FTC and PTC starts at PTS 
<20	mm	and	may	indicate	an	unusual	aggressive	tumor	
behavior	 in	 studied	 population;	 (2)	 highest	 cumulative	
risk for nodal and pulmonary metastases in PTC and for 
bone	metastasis	in	FTC	was	found	to	be	≥50	mm	PTS.
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